Core Laboratories
CLB
161 hedge funds and large institutions have $921M invested in Core Laboratories in 2022 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 56 increasing their positions, 55 reducing their positions, and 20 closing their positions.
50% more capital invested
Capital invested by funds: $615M → $921M (+$306M)
22% more call options, than puts
Call options by funds: $638K | Put options by funds: $524K
20% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 20
2% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 55
0.41% less ownership
Funds ownership: 98.34% → 97.93% (-0.41%)
1% less funds holding
Funds holding: 162 → 161 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$14.3M |
| 2 |
BlackRock
New York
|
+$5.4M |
| 3 |
EARNEST Partners
Atlanta,
Georgia
|
+$5.02M |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
+$4.33M |
| 5 |
GJL
Gendell Jeffrey L
|
+$3.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DLA
Douglas Lane & Associates
New York
|
-$6.98M |
| 2 |
VanEck Associates
New York
|
-$4.69M |
| 3 |
FAM
Fred Alger Management
New York
|
-$4.56M |
| 4 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
-$1.86M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.68M |
CLB Hedge Fund Activity: Q4 2022 in Review
161 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Core Laboratories (CLB) for Q4 2022, worth a combined $921M — up 50% from $615M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CLB positions and 20 closed out — a net gain of 4 holders — while 56 added to existing stakes and 55 trimmed.
The largest buyer was Royce & Associates, opening a new position worth an estimated $14.3M. The largest seller was Douglas Lane & Associates, cutting an estimated $6.98M.
- 161 institutional investors held Core Laboratories (CLB) as of Q4 2022, down from 162 in Q3 2022.
- Funds reported $921M of Core Laboratories stock for Q4 2022, up 50% quarter-over-quarter.
- 24 funds opened new Core Laboratories positions in Q4 2022 and 20 closed out, a net change of +4 holders.
- The largest Core Laboratories buyer in Q4 2022 was Royce & Associates, an estimated $14.3M added.
- The largest Core Laboratories seller in Q4 2022 was Douglas Lane & Associates, an estimated $6.98M sold.
Based on aggregated 13F filings for Q4 2022.